These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20065578)

  • 21. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
    Zhang Y; Kolesar JM
    Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
    Ali S; Gassas A; Kirby-Allen M; Krueger J; Ali M; Schechter T
    Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
    Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
    Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales.
    Allen R; Bryden P; Grotzinger KM; Stapelkamp C; Woods B
    Value Health; 2016; 19(5):614-22. PubMed ID: 27565278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
    Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
    Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of severe thrombocytopenia associated with systemic lupus erythematosus in pregnancy with eltrombopag: A case report and literature review.
    Leng Q; Wang W; Wang Y; Wu L
    J Clin Pharm Ther; 2021 Apr; 46(2):532-538. PubMed ID: 33277725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic assessment of eltrombopag in the treatment of thrombocytopenia.
    Romano F; Ruggeri M; Coretti S; Giannini EG; Sacchini D; Annichiarico BE; Marchetti M; Rodeghiero F; Lidonnici D
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):713-20. PubMed ID: 26176754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
    Kellum A; Jagiello-Gruszfeld A; Bondarenko IN; Patwardhan R; Messam C; Mostafa Kamel Y
    Curr Med Res Opin; 2010 Oct; 26(10):2339-46. PubMed ID: 20735290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
    Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
    Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
    Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
    Sci Rep; 2018 Jan; 8(1):576. PubMed ID: 29330464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y; Shaaban H; Gauchan D; Maroules M
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.
    Kolanis S; Vasileiou E; Hatzipantelis E; Economou M; Tragiannidis A
    Cardiovasc Hematol Agents Med Chem; 2021; 19(1):83-92. PubMed ID: 32914722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eltrombopag.
    Bussel JB; Pinheiro MP
    Cancer Treat Res; 2011; 157():289-303. PubMed ID: 21052963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.
    Grotzinger KM; Younossi ZM; Giannini EG; Chen PJ; Rendas-Baum R; Theodore D
    Health Qual Life Outcomes; 2016 Mar; 14():49. PubMed ID: 27004952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
    Dmytrijuk A; Robie-Suh K; Rieves D; Pazdur R
    Oncology (Williston Park); 2009 Nov; 23(13):1171-7. PubMed ID: 20043468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
    Ahmed S; Bashir Q; Bassett R; Poon MC; Valdez B; Konoplev S; Alousi AM; Andersson BS; Ciurea S; Hosing C; Jones R; Kebriaei P; Khouri I; Kim S; Nieto Y; Olson A; Oran B; Parmar S; Qazilbash MH; Rezvani K; Shah N; Shpall EJ; Champlin R; Popat U
    Transplant Cell Ther; 2021 May; 27(5):430.e1-430.e7. PubMed ID: 33965187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eltrombopag in patients with chronic liver disease.
    Giannini EG; Afdhal NH
    Expert Opin Pharmacother; 2013 Apr; 14(5):669-78. PubMed ID: 23452139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.